CAM
HBIO icon

ClariVest Asset Management’s Harvard Bioscience HBIO Stock Holding History

ClariVest Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$326K Hold
11,427
– – 0.03% 367
2024
Q2 		$326K Buy
11,427
+323
+3% +$11.3K 0.03% 367
2024
Q1 		$471K Buy
11,104
+21
+0.2% +$944 0.05% 361
2023
Q4 		$593K Sell
11,083
-3,406
-24% -$154K 0.03% 347
2023
Q3 		$623K Sell
14,489
-5,384
-27% -$248K 0.03% 320
2023
Q2 		$1.09M Buy
19,873
+6,759
+52% +$371K 0.05% 235
2023
Q1 		$551K Sell
13,114
-16
-0.1% -$475 0.02% 370
2022
Q4 		$364K Sell
13,130
-190
-1% -$4.68K 0.02% 404
2022
Q3 		$341K Buy
13,320
+2,610
+24% +$86.3K 0.02% 400
2022
Q2 		$385K Sell
10,710
-120
-1% -$5.42K 0.02% 411
2022
Q1 		$672K Sell
10,830
-1,560
-13% -$92.3K 0.03% 339
2021
Q4 		$873K Sell
12,390
-200
-2% -$14.2K 0.03% 344
2021
Q3 		$879K Sell
12,590
-80
-0.6% -$6.37K 0.03% 338
2021
Q2 		$1.05M Hold
12,670
– – 0.04% 284
2021
Q1 		$692K Buy
12,670
+611
+5% +$29.7K 0.02% 353
2020
Q4 		$517K Sell
12,059
-170
-1% -$6.34K 0.02% 373
2020
Q3 		$368K Sell
12,229
-720
-6% -$24.2K 0.01% 392
2020
Q2 		$401K Sell
12,949
-2,490
-16% -$67.1K 0.01% 437
2020
Q1 		$341K Sell
15,439
-741
-5% -$20.1K 0.01% 435
2019
Q4 		$493K Sell
16,180
-150
-0.9% -$4.32K 0.01% 428
2019
Q3 		$502K Sell
16,330
-262
-2% -$6.51K 0.01% 409
2019
Q2 		$331K Sell
16,592
-160
-1% -$4.69K 0.01% 400
2019
Q1 		$721K Sell
16,752
-1,567
-9% -$56.8K 0.01% 430
2018
Q4 		$582K Sell
18,319
-2,110
-10% -$83.2K 0.01% 447
2018
Q3 		$1.07M Sell
20,429
-1,230
-6% -$69K 0.02% 413
2018
Q2 		$1.16M Buy
21,659
+160
+0.7% +$8.2K 0.02% 421
2018
Q1 		$1.07M Buy
21,499
+5,449
+34% +$244K 0.02% 418
2017
Q4 		$530K Hold
16,050
– – 0.01% 481
2017
Q3 		$602K Buy
16,050
+130
+0.8% +$3.85K 0.01% 374
2017
Q2 		$406K Sell
15,920
-40
-0.3% -$990 0.01% 408
2017
Q1 		$415K Sell
15,960
-4,958
-24% -$143K 0.01% 406
2016
Q4 		$638K Buy
20,918
+1,069
+5% +$27.2K 0.02% 383
2016
Q3 		$541K Sell
19,849
-134
-0.7% -$3.72K 0.02% 371
2016
Q2 		$571K Buy
19,983
+750
+4% +$23.9K 0.02% 358
2016
Q1 		$581K Buy
19,233
+150
+0.8% +$4.25K 0.02% 344
2015
Q4 		$662K Buy
19,083
+2,807
+17% +$96K 0.02% 326
2015
Q3 		$616K Sell
16,276
-1,728
-10% -$80.4K 0.02% 314
2015
Q2 		$1.03M Sell
18,004
-149
-0.8% -$8.48K 0.03% 279
2015
Q1 		$1.06M Buy
18,153
+5,653
+45% +$304K 0.03% 283
2014
Q4 		$708K Buy
12,500
+1,850
+17% +$88.2K 0.03% 257
2014
Q3 		$436K Buy
+10,650
New +$490K 0.02% 281

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ClariVest Asset Management's HBIO Position: Q3 2024 in Review

ClariVest Asset Management held its Harvard Bioscience (HBIO) position steady in Q3 2024 at 11,427 shares worth $326K. The position accounts for 0.03% of the portfolio, ranked #367.

ClariVest Asset Management first reported a position in HBIO in Q3 2014 and has held it in 41 quarters since. The position peaked at $1.16M in Q2 2018. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2024.

  • ClariVest Asset Management held 11,427 shares of Harvard Bioscience worth $326K as of Q3 2024.
  • ClariVest Asset Management left its Harvard Bioscience share count unchanged in Q3 2024.
  • Harvard Bioscience made up 0.03% of ClariVest Asset Management's portfolio in Q3 2024, its #367 holding.
  • ClariVest Asset Management first reported a position in Harvard Bioscience in Q3 2014 and has held it in 41 quarters since.
  • ClariVest Asset Management's Harvard Bioscience position peaked at $1.16M in Q2 2018.
  • 94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.